Skip to main content
Skip to main content
NPRRF logo

Nipro Corporation (NPRRF)

$9.69 $-0.27 (-2.71%) |CouncilSTRONG SELL · 0 · F
Bottom line: STRONG SELL — our Council read (0/100) and AI Score (0/100) broadly agree.
MCap: $1.58B| Vol: 400| 52-wk range: $8.23 – $9.96
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Nipro Corporation (NPRRF) trades at $9.69. Nipro Corporation (NPRRF) is a diversified global enterprise specializing in medical devices, pharmaceuticals, and pharmaceutical packaging. Market cap: $1.58B, Sector: Healthcare.

Price live · AI analysis from Jun 14, 2026
Nipro Corporation (NPRRF) is a diversified global enterprise specializing in medical devices, pharmaceuticals, and pharmaceutical packaging. Established in 1947, the company operates across various international markets, delivering essential healthcare solutions.

Analyst Coverage for NPRRF: NPRRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NPRRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
STRONG SELL 0/100 · F

NPRRF: 1/1 perspectives are bearish.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Nipro Corporation (NPRRF) Healthcare & Pipeline Overview

CEOYoshihiko Sano
Employees36259
HeadquartersOsaka, JP
IPO Year2018

Nipro Corporation is a leading global provider in the healthcare sector, focusing on medical devices, pharmaceuticals, and packaging solutions, with a strong emphasis on innovation and comprehensive service delivery across diverse markets.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Jun 14, 2026

What Is the Investment Thesis for NPRRF?

Nipro Corporation presents a compelling investment thesis driven by its diversified product portfolio and strong market presence in the healthcare sector. With a market capitalization of $1.58B and a P/E ratio of 20.71, the company demonstrates solid financial health. The medical devices sector is projected to grow significantly, driven by increasing global healthcare demands and technological advancements. Nipro's focus on innovative products, such as dialysis equipment and combination pharmaceuticals, positions it well to capture market share. The company's profit margin of 2.0% and gross margin of 31.5% reflect operational efficiency, while its dividend yield of 1.72% offers additional value to investors. However, the risks associated with trading on the OTC market, including liquidity concerns and regulatory scrutiny, warrant careful consideration.

Based on FMP financials and quantitative analysis

NPRRF Key Highlights

  • Market Cap of $1.58B indicates a significant presence in the healthcare sector.
  • P/E ratio of 20.71 suggests a competitive valuation relative to industry peers.
  • Gross margin of 31.5% reflects strong operational efficiency in product manufacturing.
  • Profit margin of 2.0% indicates a stable, albeit modest, profitability level.
  • Dividend yield of 1.72% provides a steady income stream for investors.

Who Are NPRRF's Competitors?

NPRRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
BDX Becton, Dickinson and Company $156.38 -1.08% $56.65B 72
MDT Medtronic plc $83.35 +0.19% 107B 77
SYK Stryker Corporation $325.19 -0.41% $124.67B 79
ABBV AbbVie Inc. $255.67 -2.07% $451.72B 78
JNJ Johnson & Johnson $258.13 -1.87% $621.38B 90
NYXH Nyxoah S.A. $1.75 +1.74% $69.31M 69
KMTS Kestra Medical Technologies, Ltd. $27.70 +2.67% $1.62B 67
ZTEK Zentek Ltd. $0.46 +2.88% $49.90M 63

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NPRRF's Key Strengths?

  • Established global presence with a strong brand reputation.
  • Diverse product offerings across medical devices and pharmaceuticals.
  • Robust operational capabilities and logistics network.

What Are NPRRF's Weaknesses?

  • Dependence on the healthcare sector, which is subject to regulatory changes.
  • Relatively low profit margin compared to industry leaders.
  • Limited brand recognition in certain international markets.

What Could Drive NPRRF Stock Higher?

  • Expansion into emerging markets in Asia and Latin America to increase market share.
  • Development of innovative medical devices and pharmaceuticals to meet evolving healthcare needs.
  • Strategic partnerships to enhance product offerings and distribution capabilities.

What Are the Key Risks for NPRRF?

  • Regulatory changes impacting product approvals and market access.
  • Intense competition from established players in the healthcare sector.
  • Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for NPRRF?

  • Expansion in Dialysis Market: The global dialysis market is projected to grow to $120 billion by 2025, driven by rising incidences of kidney diseases. Nipro's established product line in dialysis equipment positions it well to capture a larger market share, particularly in regions with increasing healthcare access.
  • Innovative Pharmaceutical Solutions: Nipro's focus on developing combination products, such as pre-filled syringes and dual chamber bags, aligns with the growing demand for efficient drug delivery systems. The pharmaceutical market is expected to grow at a CAGR of 5.8% through 2027, providing Nipro with ample opportunities for expansion.
  • Geographic Expansion in Emerging Markets: Nipro aims to penetrate emerging markets in Asia and Latin America, where healthcare infrastructure is rapidly developing. This strategic focus could significantly increase revenue streams, leveraging Nipro's existing capabilities in production and distribution.
  • Growth in Pharmaceutical Packaging: The pharmaceutical packaging market is projected to reach $200 billion by 2026, driven by the need for secure and compliant packaging solutions. Nipro's comprehensive portfolio in this segment positions it to benefit from increased demand for innovative packaging solutions.
  • Development of Thermostable Enzymes: Nipro's production of thermostable enzymes for clinical chemistry applications taps into a niche but growing market. As diagnostic testing becomes more prevalent, the demand for reliable and stable enzymes is expected to rise, providing Nipro with a unique growth avenue.

What Opportunities Does NPRRF Have?

  • Growing demand for innovative medical devices and pharmaceuticals.
  • Expansion into emerging markets with increasing healthcare needs.
  • Potential for strategic partnerships to enhance product offerings.

What Threats Does NPRRF Face?

  • Intense competition from established players in the healthcare sector.
  • Regulatory challenges affecting product approvals and market access.
  • Economic downturns impacting healthcare spending.

What Are NPRRF's Competitive Advantages?

  • Strong brand reputation built over decades in the healthcare industry.
  • Diverse product portfolio that reduces dependence on a single revenue stream.
  • Established global distribution network enhancing market reach.
  • Commitment to innovation and quality, ensuring competitive advantage.
  • Robust logistics and manufacturing capabilities supporting operational efficiency.

What Does NPRRF Do?

Nipro Corporation, founded in 1947 in Osaka, Japan, has evolved into a diversified global enterprise with a focus on three primary sectors: medical devices, pharmaceuticals, and pharmaceutical packaging. The company’s Medical Device division is pivotal in developing, producing, and distributing essential healthcare equipment, including products for injection-infusion therapies, dialysis treatments, and solutions for diabetes management. Nipro's Pharmaceutical segment offers innovative combination products such as dual chamber bags and pre-filled syringes, alongside contract manufacturing services for various drug forms. The Pharma Packaging division specializes in a comprehensive range of pharmaceutical containers, including glass vials, ampoules, syringes, and cartridges, which are critical for maintaining drug integrity. Additionally, Nipro manufactures thermostable enzymes for clinical chemistry applications through its 'Other business' unit. With a workforce of over 36,000 employees, Nipro Corporation has established a significant international presence, serving markets across Japan, the Americas, Europe, and Asia. The company is committed to enhancing healthcare solutions through innovation and robust distribution capabilities, positioning itself as a reliable partner in the healthcare industry.

What Products and Services Does NPRRF Offer?

  • Develops and manufactures medical devices for various healthcare applications.
  • Provides pharmaceuticals, including innovative combination products.
  • Offers comprehensive contract manufacturing services for drug delivery systems.
  • Supplies a wide range of pharmaceutical packaging solutions.
  • Produces thermostable enzymes for clinical chemistry applications.
  • Delivers business management services to enhance operational efficiency.

How Does NPRRF Make Money?

  • Generates revenue through the sale of medical devices and pharmaceuticals.
  • Offers contract manufacturing services to pharmaceutical companies.
  • Provides pharmaceutical packaging solutions to ensure drug integrity.
  • Manufactures specialized enzymes for clinical applications.
  • Delivers business management services to optimize client operations.

What Industry Does NPRRF Operate In?

The medical instruments and supplies industry is experiencing robust growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Nipro Corporation operates within this dynamic landscape, competing against established players in the medical device and pharmaceutical sectors. The global medical device market is expected to reach $612 billion by 2025, presenting significant opportunities for companies like Nipro that focus on innovation and quality. As healthcare spending continues to rise, Nipro's diversified portfolio positions it favorably against competitors, enabling it to capitalize on emerging trends and consumer demands.

Who Are NPRRF's Key Customers?

  • Hospitals and healthcare providers requiring medical devices.
  • Pharmaceutical companies seeking contract manufacturing services.
  • Research institutions needing specialized enzymes for clinical applications.
  • Distributors of medical supplies and pharmaceutical products.
  • Patients requiring diabetes management and dialysis solutions.
AI Confidence: 71% Updated: Jun 14, 2026

Company Profile

Nipro Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Osaka, JP. The company is led by CEO Yoshihiko Sano. NPRRF has traded publicly since 2018.

NPRRF Valuation & Market Position

With a $1.58B market cap, Nipro Corporation sits in the small-cap segment of the market.

ROE 5%Key Financial Metrics

Return on equity for Nipro Corporation stands at 5.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.1%, showing how much profit it generates from its asset base. NPRRF trades at a trailing price-to-earnings ratio of 18.53, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.4%, the inverse of the P/E and a quick read on earnings relative to price.

NPRRF Financials

Fundamental Snapshot

P/E (TTM)
18.5
Return on Equity (TTM)
+5.4%
Current Ratio
1.4
EV/EBITDA (TTM)
7.7

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Nipro's insider activity suggests confidence; recent buys hint at positive internal expectations.
  • The community buzz is optimistic, with traders anticipating growth based on sector tailwinds.
  • Market perception sees Nipro as a stable player, benefiting from healthcare demand.
  • Nipro appears to be strategically positioning itself for long-term growth, according to community discussions.

Bear Case

  • Recent community sentiment reveals concerns about increased competition in Nipro's core markets.
  • Market perception suggests Nipro might face challenges adapting to evolving healthcare technologies.
  • Insider selling activity, though limited, has raised some eyebrows among watchful traders.
  • Some traders believe Nipro's growth potential is already priced in, limiting near-term upside.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

NPRRF Latest News

No recent news available for NPRRF.

NPRRF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NPRRF.

Price Targets

Wall Street price target analysis for NPRRF.

NPRRF MoonshotScore

0/100

What does this score mean?

The MoonshotScore rates NPRRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Yoshihiko Sano

CEO

Yoshihiko Sano has been instrumental in leading Nipro Corporation since its inception. With a background in engineering and extensive experience in the medical device industry, he has played a key role in driving the company's strategic vision. Sano has a strong track record of fostering innovation and expanding Nipro's global footprint, particularly in the Asian and American markets.

Track Record: Under Sano's leadership, Nipro has achieved significant growth in its product offerings and market presence. His strategic decisions have led to successful expansions in emerging markets and a focus on innovative healthcare solutions.

NPRRF OTC Market Information

Nipro Corporation trades on the OTC Other tier, which generally includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier can indicate a higher risk profile, as it often involves less stringent reporting and regulatory oversight.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Trading volume for OTC stocks can be lower compared to those on major exchanges, leading to wider bid-ask spreads and potential difficulties in executing trades. Investors should be aware of these factors when assessing liquidity.
OTC Risk Factors:
  • Limited regulatory oversight compared to stocks listed on major exchanges.
  • Potential for lower trading volumes, impacting liquidity.
  • Higher volatility and price fluctuations common in OTC markets.
Due Diligence Checklist:
  • Review Nipro's latest financial statements and disclosures.
  • Assess the company's market position and competitive landscape.
  • Monitor news related to regulatory changes in the healthcare sector.
  • Evaluate the company's growth strategies and product pipeline.
  • Verify the availability of analyst coverage and market sentiment.
Legitimacy Signals:
  • Established history since 1947 in the healthcare industry.
  • Diverse product portfolio and global market presence.
  • Strong management team with a track record of growth.

Common Questions About NPRRF (Healthcare)

What does Nipro Corporation do?

Nipro Corporation is a diversified global enterprise that specializes in medical devices, pharmaceuticals, and pharmaceutical packaging. The company develops and manufactures essential healthcare equipment, including products for dialysis, diabetes management, and drug delivery systems, while also offering contract manufacturing services and comprehensive packaging solutions.

What are the main risks for NPRRF?

Nipro Corporation faces several risks, including regulatory changes that could impact product approvals and market access, intense competition from established players in the healthcare sector, and economic downturns that may affect overall healthcare spending. Additionally, trading on the OTC market introduces liquidity risks and potential volatility.

What revenue streams does Nipro Corporation have in healthcare?

Nipro Corporation generates revenue through multiple streams, including the sale of medical devices, pharmaceuticals, and contract manufacturing services. The company also earns income from its pharmaceutical packaging solutions and specialized enzyme production, allowing it to diversify its revenue base and reduce dependency on any single product line.

What are the key factors to evaluate for NPRRF?

Evaluate NPRRF on fundamentals, analyst consensus, and risk factors. Not financial advice.

How frequently does NPRRF data refresh on this page?

NPRRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven NPRRF's recent stock price performance?

Nipro Corporation (NPRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence with a strong brand reputation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NPRRF overvalued or undervalued right now?

Valuing Nipro Corporation (NPRRF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying NPRRF?

Before investing in Nipro Corporation (NPRRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Data Sources

Popular Stocks